Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) for the reporting period of June 28, 2021. The registrant is a Delaware corporation with principal executive offices in South San Francisco, CA, and its common stock trades on Nasdaq under the symbol CBIO.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material event reported is the receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the Company's investigational drug, Marzeptacog alfa (activated) (MarzAA). Key details include:
- Product: MarzAA, a next-generation engineered coagulation Factor VIIa (FVIIa).
- Administration: Subcutaneous (SQ).
- Indication: Treatment of episodic bleeding in subjects with Factor VII deficiency.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the FDA designation. No specific financial guidance, forward-looking revenue projections, or management commentary on financial outlook is included in this document. The filing does not explicitly list new risks or contingencies beyond the standard regulatory development context implied by the Fast Track designation.
Investor Verification Checklist
- Verify the press release (Exhibit 99.1) for detailed clinical context regarding MarzAA.
- Confirm the status of the Fast Track Designation on the FDA website.
- Review the Company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains none.
- Monitor upcoming clinical trial updates for MarzAA to assess the commercial potential of the Fast Track designation.